Cough News and Research

RSS

Prestige Brands third quarter net revenues increase 17.3% to $106.3M

Prestige Brands Holdings, Inc. today announced results for the fiscal 2012 third quarter ended December 31, 2011, including net revenues of $106.3 million, an increase of 17.3% over the prior year's comparable quarter of $90.6 million.

9 Feb 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Asian bird flu update for Ferbruary 2012

Health workers in Nepal are to cull thousands of chickens following the discovery of the H5N1 strain of bird flu in the southeastern part of the Himalayan country.

6 Feb 2012

Potential way to block second wave of death from pneumonia treatment

An international research team may have found a way to block a second wave of death that can result from pneumonia treatment.

1 Feb 2012

CAT can assess exacerbation severity in patients with COPD

Exacerbation severity in patients with chronic obstructive pulmonary disease (COPD) can be reliably assessed with the COPD Assessment Test- (CAT), according to a new study from the UK.

27 Jan 2012

No whooping cough deaths in California in one whole year

The news comes after the state experienced a whooping cough epidemic in 2010 when 9,000 were infected. Most vulnerable to the disease are infants too young to be fully immunized. Ten babies died after exposure from adults or older children. The last year in which no one died was 1991, when the state recorded just 249 cases of pertussis.

24 Jan 2012

Pernix obtains marketing rights to new gastroenterology product in the U.S.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced it has entered into a license and supply agreement with a private company for a new FDA-approved prescription product to treat gastroenterology disease.

24 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

Accelerated growth may increase risk of asthma symptoms in young children

Accelerated growth in the first three months of life, but not fetal growth, is associated with an increased risk of asthma symptoms in young children, according to a new study from The Generation R Study Group at Erasmus Medical Center in the Netherlands.

20 Jan 2012

Office-based medical practice can promote vaccination in adults

Promoting immunizations as a part of routine office-based medical practice is needed to improve adult vaccination rates, a highly effective way to curb the spread of diseases across communities, prevent needless illness and deaths, and lower health care costs, according to a new RAND Corporation study.

12 Jan 2012

Occasional marijuana use does not affect lung function: Study

A new study published in the Journal of the American Medical Association has shown that an occasional drag on marijuana does not appear to have long-term adverse effects on lung function.

11 Jan 2012

Questions continue about the health law's future

CQ HealthBeat reports on the courses available for the law's implementation as stakeholders await the Supreme Court's rulings. Politico Pro reports that the recent denials by the Department of Health and Human Services regarding state medical-loss ratio adjustment requests is very different than earlier experiences.

11 Jan 2012

Nigerian leaders sign onto Gates immunization challenge

"Nigeria's 36 Executive Governors and the Federal Capital Territory have signed up to the Nigeria Immunization Challenge launched by the Bill & Melinda Gates Foundation last year," a Gates Foundation press release states.

10 Jan 2012

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.

From Baxter International Inc. 9 Jan 2012

USPTO issues patent to Tris Pharma's OralXR+ platform

Tris Pharma, an emerging specialty pharmaceutical company, announced the US grant of its core technology patent for its OralXR+ platform. This is the first patent grant of a substantial estate filed by Tris Pharma and covers a multitude of actives having modified release formulations comprising drug-ion exchange resin complexes.

7 Jan 2012